Welcome to the forum! A couple of days ago I read that research peer review in Nature. I was looking at other abstract reports and peer reviews specifically for peptide vaccines or T Cell strategy. NuGenerex certainly was or perhaps still is on the right path, because as promising as all of the available data is on this and other similar immunotherapuetic approaches, none are as potent without the patented Ii-Key tech to increase potency by around 250%.
What we don’t see since Joe took the helm is peer reviewed data. It was common years ago in a variety of preclinical or Ph 1 and 2 studies. Peer review articles, like the one you cite ushers in credibility. Generex can’t just tout a trademark, or talk other tech down, they need to present science. And I have no doubt it would be more potent, and certainly as safe, as this example or any other. Where the Ii-Key SARS Covid peer review we heard was coming actually is remains a mystery.
Generex Biotechnology Corp. (GNBT) Stock Research Links